JPRN-UMIN000030936
Recruiting
Phase 2
A randomized phase II study to evaluate efficacy of negative pressure wound therapy on prophylaxis of the incisional hernia after reversal of temporaly diverting stoma - Negative pressure wound therapy on the prophylaxis of the incisional hernia
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- temporally diverting stoma to be planned to have closed
- Sponsor
- Aichi Medical University
- Enrollment
- 70
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •severe skin disease
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Evaluation of 2nd or 3rd line treatment by Nivolumab monotherapy or Nivolumab plus Ipilimumab, for unresectable Mesothelioma patientsEUCTR2015-004475-75-FRIFCT114
Active, not recruiting
Phase 1
A randomized study to explore the efficacy and feasibility of rotations between sunitinib and everolimus versus sequential treatment of sunitinib and everolimus until progression in patients with renal cancer.EUCTR2012-001337-13-ESAPRO115
Active, not recruiting
Phase 1
A randomized study to explore the efficacy and feasibility of rotations between sunitinib and everolimus versus sequential treatment of sunitinib and everolimus until progression in patients with renal cancer.Metastatic clear cell renal cancerMedDRA version: 14.1Level: LLTClassification code 10038416Term: Renal clear cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-001337-13-GRAPRO115
Completed
Phase 2
A randomized phase II study to explore the efficacy and feasibility of upfront bi-monthly rotations between Everolimus and Pazopanib with sequential treatment of first line Pazopanib and second line Everolimus until progression in patients with advanced or metastatic clear cell renal cancer.10038364Kidney cancerRenal cancerNL-OMON39600Werkgroep Immunotherapie Nederland voor Oncologie100
Active, not recruiting
Phase 1
A study to investigate if alternating Pazopanib and Everolimus avoids or postpones resistanceEUCTR2011-000127-32-NLWerkgroep Immunotherapie Nederland voor Oncologie100